Forbes June 14, 2024
The early stages of any new, clinically impactful drug put pressure on benefit leaders. While research evolves at a pace that keeps health care professionals on their toes, benefit leaders must make precise decisions that have a big impact on the people they cover and their organization.
There’s no historical parallel to the situation benefit leaders currently face with GLP-1s. More than 50% of the U.S. adults meet the FDA’s eligibility criteria to use GLP-1s for chronic weight management, and they’re understandably concerned about the coverage costs for a drug with this level of demand.
That’s a big reason why “deprescribing” often comes up when I meet with benefit leaders. Their belief is that once the combination of GLP-1s and...
Today's Sponsors
Today's Sponsor